237 related articles for article (PubMed ID: 11495579)
1. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.
Thomas JB; Atkinson RN; Rothman RB; Fix SE; Mascarella SW; Vinson NA; Xu H; Dersch CM; Lu Y; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2001 Aug; 44(17):2687-90. PubMed ID: 11495579
[TBL] [Abstract][Full Text] [Related]
2. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
4. Characterization of BU09059: a novel potent selective κ-receptor antagonist.
Casal-Dominguez JJ; Furkert D; Ostovar M; Teintang L; Clark MJ; Traynor JR; Husbands SM; Bailey SJ
ACS Chem Neurosci; 2014 Mar; 5(3):177-84. PubMed ID: 24410326
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
[TBL] [Abstract][Full Text] [Related]
6. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
[TBL] [Abstract][Full Text] [Related]
7. Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.
Runyon SP; Brieaddy LE; Mascarella SW; Thomas JB; Navarro HA; Howard JL; Pollard GT; Carroll FI
J Med Chem; 2010 Jul; 53(14):5290-301. PubMed ID: 20568781
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
Cueva JP; Cai TB; Mascarella SW; Thomas JB; Navarro HA; Carroll FI
J Med Chem; 2009 Dec; 52(23):7463-72. PubMed ID: 19954245
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
Thomas JB; Mascarella SW; Rothman RB; Partilla JS; Xu H; McCullough KB; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 May; 41(11):1980-90. PubMed ID: 9599247
[TBL] [Abstract][Full Text] [Related]
10. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-isoquinolinecarboxamide (JDTic) analogues: in vitro pharmacology and ADME profile.
Kormos CM; Gichinga MG; Maitra R; Runyon SP; Thomas JB; Brieaddy LE; Mascarella SW; Navarro HA; Carroll FI
J Med Chem; 2014 Sep; 57(17):7367-81. PubMed ID: 25133923
[TBL] [Abstract][Full Text] [Related]
13. Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.
Melief EJ; Miyatake M; Carroll FI; Béguin C; Carlezon WA; Cohen BM; Grimwood S; Mitch CH; Rorick-Kehn L; Chavkin C
Mol Pharmacol; 2011 Nov; 80(5):920-9. PubMed ID: 21832171
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
[TBL] [Abstract][Full Text] [Related]
15. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
Le Bourdonnec B; Barker WM; Belanger S; Wiant DD; Conway-James NC; Cassel JA; O'Neill TJ; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2008 Mar; 18(6):2006-12. PubMed ID: 18313920
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
17. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).
Ondachi PW; Kormos CM; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
J Med Chem; 2018 Sep; 61(17):7525-7545. PubMed ID: 30117738
[TBL] [Abstract][Full Text] [Related]
18. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
Mitch CH; Leander JD; Mendelsohn LG; Shaw WN; Wong DT; Cantrell BE; Johnson BG; Reel JK; Snoddy JD; Takemori AE
J Med Chem; 1993 Oct; 36(20):2842-50. PubMed ID: 8410999
[TBL] [Abstract][Full Text] [Related]
19. Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.
Munro TA; Huang XP; Inglese C; Perrone MG; Van't Veer A; Carroll FI; Béguin C; Carlezon WA; Colabufo NA; Cohen BM; Roth BL
PLoS One; 2013; 8(8):e70701. PubMed ID: 23976952
[TBL] [Abstract][Full Text] [Related]
20. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
